Literature DB >> 11173574

Role of Proteoglycans in Tumor Progression.

József Timár1, András Jeney, László Kopper.   

Abstract

Data is now starting to accumulate on the differential expression of PGs in tumor cells of various invasive/metastatic potential. This is not so surprising if one considers the key functions that PGs play in the regulation of cell proliferation, adhesion and motility. However, characterization of PG expression in individual tumor types still awaits further detailed studies. Data on melanomas clearly indicate that PG phenotype is both specific and also promiscuous in a sense that ectopic expression of certain tissue specific PGs can occur in various tumors. Expression of a metastatic phenotype-specific splice variants of CD44 provides an example for the possible marker-function of PG. This also raises the hope that some PGs could be used as diagnostic/prognostic tools in pathology or even as a therapeutic targets against tumor dissemination. On the other hand, specific glycanation inhibitors may also be used for the modulation of tumor PG exist and the invasive phenotype.

Entities:  

Year:  1995        PMID: 11173574     DOI: 10.1007/bf02893590

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  57 in total

1.  Flow cytometric analysis of proteoglycan expression on murine tumor cells with different metastatic capacity.

Authors:  J Timár; K Lapis
Journal:  Anticancer Res       Date:  1990 May-Jun       Impact factor: 2.480

Review 2.  Proteoglycans: structures and interactions.

Authors:  L Kjellén; U Lindahl
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

Review 3.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

4.  Interactions of exogenous heparan sulfate with tumor cells of different metastatic phenotype.

Authors:  J Timar; M Moczar; K Lapis; E Moczar
Journal:  Invasion Metastasis       Date:  1990

5.  Isolation and characterization of proteoglycans from human nonepithelial tumors.

Authors:  M Sobue; J Takeuchi; K Yoshida; S Akao; T Fukatsu; T Nagasaka; N Nakashima
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

6.  Interactions of thrombospondin with sulfated glycolipids and proteoglycans of human melanoma cells.

Authors:  D D Roberts
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

7.  Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation.

Authors:  P Inki; F Stenbäck; L Talve; M Jalkanen
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

8.  Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin.

Authors:  J Iida; A P Skubitz; L T Furcht; E A Wayner; J B McCarthy
Journal:  J Cell Biol       Date:  1992-07       Impact factor: 10.539

9.  Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells.

Authors:  A Godal; O Bruland; E Haug; M Aas; O Fodstad
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

10.  CD44H regulates tumor cell migration on hyaluronate-coated substrate.

Authors:  L Thomas; H R Byers; J Vink; I Stamenkovic
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

View more
  3 in total

1.  Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p.

Authors:  Z Adám; R Adány; A Ladányi; J Tímár; M Balázs
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Expression of a decorin-like moleculein human melanoma.

Authors:  A Ladányi; M Gallai; S Paku; J O Nagy; J Dudás; J Tímár; I Kovalszky
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Radial scar-significant diagnostic challenge.

Authors:  Zsófia Egyed; Zoltán Péntek; Balázs Járay; Janina Kulka; Egon Svastics; József Kas; Zsolt László
Journal:  Pathol Oncol Res       Date:  2008-04-12       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.